摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Bromo-1-(3,4-dibromo-phenyl)-ethanone | 556110-55-5

中文名称
——
中文别名
——
英文名称
2-Bromo-1-(3,4-dibromo-phenyl)-ethanone
英文别名
2-bromo-1-(3,4-dibromophenyl)ethanone
2-Bromo-1-(3,4-dibromo-phenyl)-ethanone化学式
CAS
556110-55-5
化学式
C8H5Br3O
mdl
——
分子量
356.839
InChiKey
TUQODQYAMJTNTQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    CH557384
    摘要:
    公开号:
  • 作为产物:
    描述:
    溴乙酰溴1,2-二溴苯 以13%的产率得到2-Bromo-1-(3,4-dibromo-phenyl)-ethanone
    参考文献:
    名称:
    Compounds and their therapeutic use
    摘要:
    公式I的化合物:其中:X代表—CH₂CH—、—CH₂CR—、—CR₂CR—、—CO—、—O—、—NH—、—NR—、S—、—SO—、—SO₂—、—CH₂N—、—CR₂N—、—CH₂N(O)—、—CR₂N(O)—或任何其他能够形成S—或6元杂环的原子或原子团;Y₁、Y₂和Y₃独立地代表氢或卤素;R₁、R₂和R₃独立地代表氢、卤素、烃基(—R)、羟基(—OH)、烃氧基(—O—R)、巯基(—SH)、烃硫基(—S—R)、烃基磺基(—SO—R)、烃基磺酰基(—SO₂—R)、硝基(—NO₂)、氨基(—NH₂)、烃基氨基(—NHR)、双(烃基)氨基(—NR₂)、烃基羰基氨基(—NH—CO—R)、氰基(—CN)、氨基甲酰基(—CONH₂)、烃基甲酰胺基(—CONHR)、双(烃基)氨基甲酰基(—CONR₂)、羧基(—CO₂H)、烃氧羰基(—CO₂R)、甲酰基(—CHO)、烃基羰基(—COR)、烃基羰氧基(—OCOR)、可选地取代的杂芳烃或可选地取代的杂环;烃基R为直链或支链烃基,选自烷基、烯基、炔基、芳基、芳基烷基、芳基烯基和芳基炔基,该基团可以选择地被一个或多个取代基取代,所述取代基选自与R₁、R₂和R₃相关定义的那些取代基;用于制造一种药物,用于治疗包括预防GSK-3激活介导的疾病的药物。
    公开号:
    US20030199508A1
点击查看最新优质反应信息

文献信息

  • CHALCONE DERIVATIVE COMPOUNDS
    申请人:NIPPON OIL AND FATS COMPANY, LIMITED
    公开号:EP0328669A1
    公开(公告)日:1989-08-23
    Chalcone derivative compounds represented by general formula (I) or (II), wherein R₁ and R₂ each represents a ha­logen atom, a hydroxy group, an amino group, a dimethylamino group, a nitro group, a cyano group, a phenyl group, an acetyl group, an alkyl group containing 1 to 18 carbon atoms or an alkyloxy group containing 1 to 22 carbon atoms, n₁ and n₂ each represents an integer of 0 to 21, and m₁ and m₂ each represents an integer of 0 to 5.
    通式(I)或(II)代表的查耳酮衍生物化合物,其中 R₁ 和 R₂ 各自代表卤素原子、羟基、氨基、二甲基氨基、硝基、氰基、苯基、乙酰基、含 1 至 18 个碳原子的烷基或含 1 至 22 个碳原子的烷氧基,n₁ 和 n₂ 各自代表整数、乙酰基、含 1 至 18 个碳原子的烷基或含 1 至 22 个碳原子的烷氧基,n₁ 和 n₂ 各自代表 0 至 21 的整数,m₁ 和 m₂ 各自代表 0 至 5 的整数。
  • US6747057B2
    申请人:——
    公开号:US6747057B2
    公开(公告)日:2004-06-08
  • [EN] COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3<br/>[FR] COMPOSES ET UTILISATION THERAPEUTIQUE RELATIVE A L'ACTIVITE DE PHOSPHORYLATION DE L'ENZYME GSK-3
    申请人:CONSEJO SUPERIOR INVESTIGACION
    公开号:WO2003055479A1
    公开(公告)日:2003-07-10
    Compounds of formula (I): wherein: X represents CH=CH-, -CH=CR-, -CR=CR-, -CO-, -O-, -NH-, -NR-, -S-, -SO-, -SO2-, -CH=N-, -CR=N-, -CH=N(O)-, -CR=N(O)- or any other atom or groug of atoms capable of forming a S- or 6- membered heterocyclic ring; Y1, Y2 and Y3 independently represent hydrogen or halogen; R1, R2 and R3 are independently represent hydrogen, halogen, hydrocarbyl (-R), hydroxyl (-OH), hydrocarbyloxy (-O-R), mercapto (-SH), hydrocarbylthio (-S-R), hydrocarbylsulfinyl (-SO-R), hydrocarbylsulfonyl (-SO2-R), nitro (-NO2), amino (-NH2), hydrocarbylamino (-NHR), bis(hydrocarbyl)amino (-NR2), hydrocarbylcarbonylamino (-NH-CO-R), cyano (-CN), carbamoyl (-CONH2), hydrocarbylcarbamoyl (-CONHR), bis(hydrocarbyl)carbamoyl (-CONR2), carboxyl (-CO2H), hydrocarbyloxycarbonyl (-CO2R), formyl (-CHO), hydrocarbylcarbonyl (-COR), hydrocarbylcarbonyloxy (-OCOR), optionally substituted heteroaryl or optionally substituted hetereocyclic; and the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be subtituted by one or more substituents, selected from those defined above in relation to R1, R2, and R3] ; are of use in the manufacture of a medicament for the treatment including prophylaxis of disease mediated by the activation of GSK-3.
  • [EN] NOVEL DERIVATIVES OF IMIDAZOLE, USE OF NOVEL DERIVATIVES OF IMIDAZOLE AND A METHOD OF MANUFACTURING THEM<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOLE, UTILISATION DES NOUVEAUX DÉRIVÉS D'IMIDAZOLE ET PROCÉDÉ DE FABRICATION DE CES DERNIERS
    申请人:UNIV MEDYCZNY IM KAROLA MARCIN
    公开号:WO2009070045A2
    公开(公告)日:2009-06-04
    The subject of the present application are derivatives of imidazole, a method of manufacturing them as well as their use as active substance in medicinal products for use in human and veterinary medicine. The derivatives of imidazole according to the present invention are compounds with the general formula (1) in which R1, R2, R3 and n have the meanings as defined in the description.
  • Compounds and their therapeutic use
    申请人:——
    公开号:US20030199508A1
    公开(公告)日:2003-10-23
    Compounds of formula I: 1 [wherein: X represents —CH═CH—, —CH═CR—, —CR═CR—, —CO—, —O—, —NH—, —NR—, S—, —SO—, —SO 2 —, —CH═N—, —CR═N—, —CH═N(O)—, —CR═N(O)— or any other atom or group of atoms capable of forming a S— or 6-membered heterocyclic ring; Y 1 , Y 2 and Y 3 independently represent hydrogen or halogen; R 1 , R 2 and R 3 are independently represent hydrogen, halogen, hydrocarbyl (—R), hydroxyl (—OH), hydrocarbyloxy (—O—R), mercapto (—SH), hydrocarbylthio (—S—R), hydrocarbylsulfinyl (—SO—R), hydrocarbylsulfonyl (—SO 2 —R), nitro (—NO 2 ), amino (—NH 2 ), hydrocarbylamino (—NHR), bis(hydrocarbyl)amino (—NR 2 ), hydrocarbylcarbonylamino (—NH—CO—R), cyano (—CN), carbamoyl (—CONH 2 ), hydrocarbylcarbarnoyl (—CONHR), bis(hydrocarbyl)carbamoyl (—CONR 2 ), carboxyl (—CO 2 H), hydrocarbyloxycarbonyl (—CO 2 R), formyl (—CHO), hydrocarbylcarbonyl (—COR), hydrocarbylcarbonyloxy (—OCOR), optionally substituted heteroaryl or optionally substituted heterocyclic; and the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R1, R2 and R3]; are of use in the manufacture of a medicament for the treatment including prophylaxis of disease mediated by the activation of GSK-3.
    公式I的化合物:其中:X代表—CH₂CH—、—CH₂CR—、—CR₂CR—、—CO—、—O—、—NH—、—NR—、S—、—SO—、—SO₂—、—CH₂N—、—CR₂N—、—CH₂N(O)—、—CR₂N(O)—或任何其他能够形成S—或6元杂环的原子或原子团;Y₁、Y₂和Y₃独立地代表氢或卤素;R₁、R₂和R₃独立地代表氢、卤素、烃基(—R)、羟基(—OH)、烃氧基(—O—R)、巯基(—SH)、烃硫基(—S—R)、烃基磺基(—SO—R)、烃基磺酰基(—SO₂—R)、硝基(—NO₂)、氨基(—NH₂)、烃基氨基(—NHR)、双(烃基)氨基(—NR₂)、烃基羰基氨基(—NH—CO—R)、氰基(—CN)、氨基甲酰基(—CONH₂)、烃基甲酰胺基(—CONHR)、双(烃基)氨基甲酰基(—CONR₂)、羧基(—CO₂H)、烃氧羰基(—CO₂R)、甲酰基(—CHO)、烃基羰基(—COR)、烃基羰氧基(—OCOR)、可选地取代的杂芳烃或可选地取代的杂环;烃基R为直链或支链烃基,选自烷基、烯基、炔基、芳基、芳基烷基、芳基烯基和芳基炔基,该基团可以选择地被一个或多个取代基取代,所述取代基选自与R₁、R₂和R₃相关定义的那些取代基;用于制造一种药物,用于治疗包括预防GSK-3激活介导的疾病的药物。
查看更多